Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Merck shared updates on the company’s oncology pipeline and focused R&D approach
With this, for all our USFDA facilities, EIRs are in place
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
The facility will manufacture tablets, capsules, and injections for the oncology segment
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
These approvals mark significant progress for Venus Remedies in expanding its market presence
The company will provide comprehensive response to USFDA for the observations
Subscribe To Our Newsletter & Stay Updated
